• Explore /
  • Poster
  • / ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.

ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.

Abstract Poster

Authors

null

Friedrich Foerster

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

Friedrich Foerster , Roman Kloeckner , Maria Reig , Stephen Lam Chan , Jin Wook Chung , Philippe Merle , Joong-Won Park , Fabio Piscaglia , Arndt Vogel , Vincent Gaillard , Jordi Bruix , Peter R. Galle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04803994

DOI

10.1200/JCO.2022.40.4_suppl.TPS498

Abstract #

TPS498

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Masatoshi Kudo

First Author: Kazuomi Ueshima

First Author: Kevin Kim

First Author: Tanios S. Bekaii-Saab